{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:32:12Z","timestamp":1790674332777,"version":"4.1.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02060","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T10:13:22Z","timestamp":1536747202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections"],"prefix":"10.3389","volume":"9","author":[{"given":"Valentina","family":"Bernasconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Bernocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Quan","family":"L\u00ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajibola","family":"Omokanye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolphe","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staeheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Betbeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-017-0918-y","article-title":"Towards a universal influenza vaccine: different approaches for one goal","volume":"15","author":"Sautto","year":"2018","journal-title":"Virol J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41541-017-0026-4","article-title":"A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies","volume":"2","author":"Nachbagauer","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coi.2018.04.015","article-title":"Influenza vaccines: 'tailor-made' or 'one fits all'","volume":"53","author":"Saletti","year":"2018","journal-title":"Curr Opin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"546274","DOI":"10.1155\/2014\/546274","article-title":"Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development","volume":"2014","author":"Khanna","year":"2014","journal-title":"Biomed Res Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.antiviral.2013.03.021","article-title":"Broadly neutralizing antibodies against influenza viruses","volume":"98","author":"Laursen","year":"2013","journal-title":"Antiviral Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1128\/CVI.00081-12","article-title":"High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza","volume":"19","author":"To","year":"2012","journal-title":"Clin Vaccine Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.4049\/jimmunol.181.6.4168","article-title":"A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza A virus","volume":"181","author":"Carragher","year":"2008","journal-title":"J Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s15010-013-0546-4","article-title":"Development of universal influenza vaccines based on influenza virus M and NP genes","volume":"42","author":"Zheng","year":"2014","journal-title":"Infection"},{"key":"B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14760584.2017.1240041","article-title":"M2-based influenza vaccines: recent advances and clinical potential","volume":"16","author":"Kolpe","year":"2017","journal-title":"Exp Rev Vaccines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: Shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0190868","DOI":"10.1371\/journal.pone.0190868","article-title":"Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS ONE"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3389\/fimmu.2017.01730","article-title":"Cross-protective efficacy of influenza virus M2e containing virus-like particles is superior to hemagglutinin vaccines and variable depending on the genetic backgrounds of mice","volume":"8","author":"Kim","year":"2017","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.vaccine.2007.12.027","article-title":"CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine","volume":"26","author":"Eliasson","year":"2008","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e85832","DOI":"10.1172\/jci.insight.85832","article-title":"Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection","volume":"1","author":"Zens","year":"2016","journal-title":"JCI Insight"},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaag2031","DOI":"10.1126\/sciimmunol.aag2031","article-title":"Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity","volume":"2","author":"Slutter","year":"2017","journal-title":"Sci Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4049\/jimmunol.1402975","article-title":"Airway-resident memory CD8 T cells provide antigen-specific protection against respiratory virus challenge through Rapid IFN-gamma production","volume":"195","author":"McMaster","year":"2015","journal-title":"J Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1189\/jlb.0313180","article-title":"Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection","volume":"95","author":"Wu","year":"2014","journal-title":"J Leukoc Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1086\/422879","article-title":"Intranasal versus injectable influenza vaccine","volume":"39","author":"Genton","year":"2004","journal-title":"Clin Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.4049\/jimmunol.167.6.3398","article-title":"CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen","volume":"167","author":"Mowat","year":"2001","journal-title":"J Immunol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.4049\/jimmunol.162.4.2432","article-title":"Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity","volume":"162","author":"Agren","year":"1999","journal-title":"J Immunol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.4049\/jimmunol.158.8.3936","article-title":"Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit","volume":"158","author":"Agren","year":"1997","journal-title":"J Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/mi.2017.14","article-title":"M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection","volume":"11","author":"Eliasson","year":"2017","journal-title":"Mucosal Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6597","DOI":"10.1016\/j.vaccine.2006.05.082","article-title":"Improved design and intranasal delivery of an M2e-based human influenza a vaccine","volume":"24","author":"De Filette","year":"2006","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.4049\/jimmunol.173.5.3310","article-title":"The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues","volume":"173","author":"Eriksson","year":"2004","journal-title":"J Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1586\/14760584.6.5.821","article-title":"Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins","volume":"6","author":"Connell","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2016.04.014","article-title":"Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles","volume":"232","author":"Bernocchi","year":"2016","journal-title":"J Control Release"},{"key":"B31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.addr.2008.09.005","article-title":"Nanoparticles for nasal vaccination","volume":"61","author":"Csaba","year":"2009","journal-title":"Adv Drug Deliv Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1016\/j.vaccine.2010.02.057","article-title":"Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types","volume":"28","author":"Zhang","year":"2010","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-bioeng-071811-150054","article-title":"Mucosal vaccine design and delivery","volume":"14","author":"Woodrow","year":"2012","journal-title":"Annu Rev Biomed Eng."},{"key":"B34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11095-009-9986-z","article-title":"Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers","volume":"27","author":"Paillard","year":"2010","journal-title":"Pharm Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.biomaterials.2015.01.056","article-title":"Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection","volume":"50","author":"Dimier-Poisson","year":"2015","journal-title":"Biomaterials"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9117","DOI":"10.1016\/j.biomaterials.2012.08.064","article-title":"Influence of surface charge and inner composition of nanoparticles on intracellular delivery of proteins in airway epithelial cells","volume":"33","author":"Dombu","year":"2012","journal-title":"Biomaterials"},{"key":"B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.it.2011.02.006","article-title":"T cell responses during influenza infection: getting and keeping control","volume":"32","author":"Kim","year":"2011","journal-title":"Trends Immunol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/MMBR.56.4.622-647.1992","article-title":"Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin","volume":"56","author":"Spangler","year":"1992","journal-title":"Microbiol Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1084\/jem.185.2.317","article-title":"Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures","volume":"185","author":"Winzler","year":"1997","journal-title":"J Exp Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5482087","DOI":"10.1155\/2016\/5482087","article-title":"Mucosal vaccine development based on liposome technology","volume":"2016","author":"Bernasconi","year":"2016","journal-title":"J Immunol Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijpharm.2017.07.012","article-title":"Nasal nanovaccines","volume":"530","author":"Bernocchi","year":"2017","journal-title":"Int J Pharm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/338765a0","article-title":"A novel MHC class II epitope expressed in thymic medulla but not cortex","volume":"338","author":"Murphy","year":"1989","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/BF01718294","article-title":"Molecular and immunological characterization of soluble aggregated A\/Victoria\/3\/75 (H3N2) influenza haemagglutinin expressed in insect cells","volume":"141","author":"Vanlandschoot","year":"1996","journal-title":"Arch Virol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jim.2014.03.023","article-title":"Animal models for influenza virus pathogenesis, transmission, and immunology","volume":"410","author":"Thangavel","year":"2014","journal-title":"J Immunol Methods"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.2147\/IJN.S154743","article-title":"Properties and applications of nanoparticle\/microparticle conveyors with adjuvant characteristics suitable for oral vaccination","volume":"13","author":"Zhang","year":"2018","journal-title":"Int J Nanomed."},{"key":"B46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","article-title":"Nanoparticle vaccines","volume":"32","author":"Zhao","year":"2014","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e33354","DOI":"10.7554\/eLife.33354","article-title":"IFN-\u03b3 prevents influenza virus spread from the upper airways to the lungs and limits virus transmission","volume":"7","author":"Klinkhammer","year":"2018","journal-title":"eLife"},{"key":"B48","doi-asserted-by":"publisher","first-page":"12825","DOI":"10.1128\/JVI.05930-11","article-title":"The DBA","volume":"85","author":"Pica","year":"2011","journal-title":"J Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1128\/JVI.01141-13","article-title":"A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2","volume":"88","author":"Herve","year":"2014","journal-title":"J Virol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1586\/erv.12.31","article-title":"Mucosal immunity and nasal influenza vaccination","volume":"11","author":"Rose","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B51","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1586\/14760584.6.2.193","article-title":"Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic","volume":"6","author":"Hasegawa","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1016\/j.vaccine.2012.04.109","article-title":"Mucosal IgA responses in influenza virus infections; thoughts for vaccine design","volume":"30","author":"van Riet","year":"2012","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0264-410X(01)00326-7","article-title":"A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains","volume":"20","author":"Babai","year":"2001","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/pharmaceutics5030392","article-title":"Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators","volume":"5","author":"Barnier-Quer","year":"2013","journal-title":"Pharmaceutics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.vaccine.2011.01.009","article-title":"A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS)","volume":"29","author":"Even-Or","year":"2011","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1016\/j.vaccine.2005.12.017","article-title":"A new intranasal influenza vaccine based on a novel polycationic lipid\u2013ceramide carbamoyl-spermine (CCS) I","volume":"24","author":"Joseph","year":"2006","journal-title":"Vaccine"},{"key":"B57","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1208\/s12249-013-0058-7","article-title":"Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine","volume":"15","author":"Sawaengsak","year":"2014","journal-title":"AAPS PharmSciTech."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.vaccine.2005.10.032","article-title":"Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells","volume":"24","author":"Waeckerle-Men","year":"2006","journal-title":"Vaccine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3389\/fimmu.2018.00934","article-title":"Mucosal immunity and protective efficacy of intranasal inactivated influenza vaccine is improved by chitosan nanoparticle delivery in pigs","volume":"9","author":"Dhakal","year":"2018","journal-title":"Front Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/nn4006544","article-title":"Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza","volume":"7","author":"Patterson","year":"2013","journal-title":"ACS Nano"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0151922","DOI":"10.1371\/journal.pone.0151922","article-title":"Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in Pigs","volume":"11","author":"Hiremath","year":"2016","journal-title":"PLoS ONE"},{"key":"B62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.vetmic.2016.11.026","article-title":"Influenza A virus vaccines for swine","volume":"206","author":"Vincent","year":"2017","journal-title":"Vet Microbiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1016\/j.vaccine.2008.09.057","article-title":"Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model","volume":"26","author":"Hagenaars","year":"2008","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/bit.25537","article-title":"Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity","volume":"112","author":"Patel","year":"2015","journal-title":"Biotechnol Bioeng."},{"key":"B65","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1016\/j.vaccine.2013.10.041","article-title":"Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques","volume":"31","author":"Vanloubbeeck","year":"2013","journal-title":"Vaccine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","article-title":"Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses","volume":"9","author":"Deng","year":"2018","journal-title":"Nat Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1016\/j.vaccine.2011.03.090","article-title":"A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus","volume":"29","author":"Eliasson","year":"2011","journal-title":"Vaccine"},{"key":"B68","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.1128\/JVI.00549-15","article-title":"Inclusion of flagellin during vaccination against influenza enhances recall responses in nonhuman primate neonates","volume":"89","author":"Kim","year":"2015","journal-title":"J Virol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1016\/j.vaccine.2016.08.010","article-title":"Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model","volume":"34","author":"Holbrook","year":"2016","journal-title":"Vaccine"},{"key":"B70","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/jmv.21415","article-title":"Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally","volume":"81","author":"Ghendon","year":"2009","journal-title":"J Med Virol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2007.12.001","article-title":"Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function","volume":"20","author":"Allen","year":"2008","journal-title":"Semin Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fimmu.2016.00225","article-title":"How follicular dendritic cells shape the B-cell antigenome","volume":"7","author":"Kranich","year":"2016","journal-title":"Front Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.4049\/jimmunol.1101107","article-title":"Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant","volume":"187","author":"Mattsson","year":"2011","journal-title":"J Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jconrel.2009.10.022","article-title":"Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen","volume":"142","author":"Henriksen-Lacey","year":"2010","journal-title":"J Control Release"},{"key":"B75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/acsnano.5b00028","article-title":"Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin","volume":"9","author":"Shan","year":"2015","journal-title":"ACS Nano"},{"key":"B77","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","article-title":"Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery","volume":"15","author":"Battaglia","year":"2018","journal-title":"Expert Opin Drug Deliv."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.4049\/jimmunol.0900995","article-title":"Critical role of IL-17RA in immunopathology of influenza infection","volume":"183","author":"Crowe","year":"2009","journal-title":"J Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1002\/eji.201343713","article-title":"Dysregulation in lung immunity - the protective and pathologic Th17 response in infection","volume":"43","author":"Way","year":"2013","journal-title":"Eur J Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"741","DOI":"10.12688\/f1000research.10862.1","article-title":"Yin and yang of interleukin-17 in host immunity to infection","volume":"6","author":"Das","year":"2017","journal-title":"F1000Res"},{"key":"B81","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1128\/JVI.72.8.6637-6645.1998","article-title":"Protective role of gamma interferon during the recall response to influenza virus","volume":"72","author":"Bot","year":"1998","journal-title":"J Virol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.virusres.2015.02.003","article-title":"Influenza virus activation of the interferon system","volume":"209","author":"Killip","year":"2015","journal-title":"Virus Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3389\/fmicb.2017.00900","article-title":"Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre","volume":"8","author":"Gould","year":"2017","journal-title":"Front Microbiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1348-0421.2008.00010.x","article-title":"Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice","volume":"52","author":"Isaka","year":"2008","journal-title":"Microbiol Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/infdis\/jiw619","article-title":"Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-Cell responses following repeated annual influenza vaccination","volume":"215","author":"Trieu","year":"2017","journal-title":"J Infect Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1021\/acschembio.7b00845","article-title":"Augmenting influenza-specific T Cell memory generation with a natural killer T Cell-dependent glycolipid-peptide vaccine","volume":"12","author":"Anderson","year":"2017","journal-title":"ACS Chem Biol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T22:01:14Z","timestamp":1693864874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,12]]},"references-count":86,"alternative-id":["10.3389\/fimmu.2018.02060"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02060","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,12]]},"article-number":"2060"}}